Related Experiment Video
Updated: Jan 17, 2026
06:46
A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19
Published on: July 5, 2022
3.2K
Young Adult Diabetes Technology Use in Pediatric as Compared to Adult Practices
Sean DeLacey1, Saketh Rompicherla2, Jody Grundman3
1Division of Endocrinology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois.
Summary
Young adults with type 1 diabetes (T1D) face challenges during the transition to adult care. Those in adult care settings showed poorer diabetes control and less technology use compared to pediatric settings.
Area of Science:
- Endocrinology
- Diabetes Management
- Public Health
Background:
- Type 1 diabetes (T1D) management in emerging adulthood presents unique challenges.
- Transitioning from pediatric to adult healthcare systems can impact disease outcomes.
- High hemoglobin A1C (HbA1C) levels are common in young adults with T1D.
Purpose of the Study:
- To compare disease outcomes and care practices for young adults (YAs) with T1D in pediatric versus adult healthcare institutions.
- To identify differences in diabetes control, complications, and technology use between care settings.
Main Methods:
- Retrospective review of T1D patients aged 18-23 years using T1D Exchange data (2022-2023).
- Categorization of patients based on care location: pediatric (n=8538) vs. adult (n=839) institutions.
- Logistic regression analysis to compare optimal/poor glycemic control (HbA1C levels), acute complications, and technology adoption.
Main Results:
- Young adults in adult institutions were older and more likely to have undocumented insurance.
- Despite high technology use in both groups, those in adult settings had poorer diabetes control (OR 1.23).
- Adult care settings were associated with lower use of continuous glucose monitors (OR 0.64) and insulin pumps (OR 0.62).
Conclusions:
- Young adults with T1D receiving care in adult institutions exhibit worse glycemic control and reduced adoption of diabetes technology compared to those in pediatric centers.
- Limitations include unequal regional representation and smaller adult center populations.
- Further research is crucial to understand and address barriers to technology use for YAs in adult practices.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
868
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
868
01:22Diabetes Mellitus: Type 2 and Gestational
4.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.3K
01:22Diabetes Mellitus: Overview and Type I Subtype
4.9K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.9K
01:15Diabetes: Symptoms, Diagnosis, and Complications
2.1K
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
2.1K
01:16Insulin: Dosing Regimen and Adverse Effects
689
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
689
01:29Drug Dosing: Infants and Children
256
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
256